Table 2 Amniotic membrane transplantation (AMT) results

From: Corneal sensitivity and ocular surface changes following preserved amniotic membrane transplantation for nonhealing corneal ulcers

Case

Method of AMT

FU (months)

Preop BCVA

Postop BCVA

Epithelial healing (days)

Epitheliali-sation phenotype

Transparency attained (months)

Stromal gain/vascularisation

Complication

Further management

1

G+F

14

HM

20/200

14

Cornea

6

+/−

None

None

2

F+G+P

12

HM

20/200

25

Cornea

4

+/+

None

None

3

1st G+F 2nd F+G+P

13

HM

20/200

23

Cornea

7

+/+

None

PKP planned, lubricants

4

G+P

8

HM

20/200

26

Cornea

5

+/+

None

PKP planned lubricants

5

G+P

10

20/60

20/40

16

Cornea

4

+/−

None

None

6

F+G+P

8

HM

20/100

16

Cornea

4

+/−

None

PKP+ECCE+IOL, lubricants

7

F+G+P

8

HM

HM

30

Conjunctiva

None

−/−

Progressive thinning

CP, lubricants

8

F+G+P

12

HM

HM

60

Conjunctiva

None

−/−

None

PKP planned, lubricants

9

G+P

12

HM

HM

32

Conjunctiva

None

−/−

None

Lubricants, LT+PKP planned

10

G+P

8

HM

HM

45

None

−/−

Superinfection graft failure

TCL, AS, lubricants, repeat PKP planned

  1. Note: G+F: graft+filling; G+P: graft+patch; F+G+P: filling+graft+patch; HM: hand motion; PKP: penetrating keratoplasty; ECCE: extracapsular cataract extraction; IOL: intraocular lens; CP: conjunctival patching; LT: limbal transplant; TCL: therapeutic contact lens; AS: autologous serum; FU: follow-up; BCVA: best-corrected visual acuity.